Biotech Values

[DewDiligence]

(RVNC)—AGN acquires private botulinum-toxin company:

http://finance.yahoo.com/news/allergan-acquires-medical-dermatology-aesthetic-130000073.html

Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential development and commercialization milestone payments related to NDS, Anterios' proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections.

In addition to NDS, Allergan has acquired global rights to ANT-1207, an investigational topical formulation botulinum toxin type A in development for the potential treatment of hyperhidrosis, acne, and crow's feet lines.

ANT-1207 sounds like a direct competitor to RVNC’s RT001. This acquisition provides more evidence that AGN is taking the commercial threat from RVNC seriously.